VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Study of P97 Inhibitors in Mantle Cell Lymphoma

Rekha Rao, PhD
Published: Wednesday, Apr 05, 2017



Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

P97 is an ATPase that restores protein to homeostasis in cells and promotes retrotranslocation of misfolded proteins from the endoplasmic reticulum (ER), says Rao.

Researchers are working to target MCL with new agents that can induce ER stress. And when p97 function is inhibited, ER Rao adds, the ER becomes stressed, suggesting that p97 inhibitors could be effective the treatment of MCL.
 


Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

P97 is an ATPase that restores protein to homeostasis in cells and promotes retrotranslocation of misfolded proteins from the endoplasmic reticulum (ER), says Rao.

Researchers are working to target MCL with new agents that can induce ER stress. And when p97 function is inhibited, ER Rao adds, the ER becomes stressed, suggesting that p97 inhibitors could be effective the treatment of MCL.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x